Deals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
Abogen BiosciencesmRNA

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Co., Ltd. ("Abogen"), a clinical‑stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis AG (NYSE: NVS) to advance…

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Fujian Haixi Pharmaceuticals Files for Hong Kong IPO
Haixi PharmaceuticalsIPO

Fujian Haixi Pharmaceuticals Files for Hong Kong IPO

Servier and Google Cloud Extend Partnership to Advance AI in Drug Development
FinanceServier Pharmaceuticals

Servier and Google Cloud Extend Partnership to Advance AI in Drug Development

Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials
Cathay BiotechFinance

Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials

Simcere Licenses Fermion's AI-Enabled Painkiller FZ002-037
BiotechFermion Technology

Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037

Show More